Cytokinetics, Incorporated
CYTK
Peringkat dalam Saham
#2305
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Harga Saham
$62.08
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$8.63B
Perubahan (1 hari)
0.21%
Perubahan (1 tahun)
4.60%
Negara
US
Perdagangan Cytokinetics, Incorporated (CYTK)
Kategori
Healthcare
Laba untuk Cytokinetics, Incorporated (CYTK)
Laba pada Jun 2026 TTM: $-894.00M
Menurut laporan keuangan terbaru dari Cytokinetics, Incorporated, laba saat ini perusahaan adalah $-894.00M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-526.24M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-388.96M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Cytokinetics, Incorporated dari 2000 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-894.00M | 51.65% |
| 2024 | $-589.53M | 12.03% |
| 2023 | $-526.24M | 35.30% |
| 2022 | $-388.96M | 80.65% |
| 2021 | $-215.31M | 69.15% |
| 2020 | $-127.29M | 4.60% |
| 2019 | $-121.69M | 14.49% |
| 2018 | $-106.29M | -16.83% |
| 2017 | $-127.79M | -876.70% |
| 2016 | $16.45M | -143.87% |
| 2015 | $-37.50M | 156.05% |
| 2014 | $-14.65M | -56.56% |
| 2013 | $-33.72M | -13.58% |
| 2012 | $-39.02M | -18.48% |
| 2011 | $-47.86M | -3.24% |
| 2010 | $-49.46M | -300.30% |
| 2009 | $24.69M | -143.80% |
| 2008 | $-56.37M | 15.30% |
| 2007 | $-48.89M | -14.39% |
| 2006 | $-57.12M | 35.18% |
| 2005 | $-42.25M | 13.59% |
| 2004 | $-37.20M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -690.03% |
US
|
|
| $-3.09B | 245.30% |
US
|
|
| $-4.02B | 349.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -318.19% |
NL
|
